Automated Nucleated Red Blood Cell Enumeration Evaluated
|
By LabMedica International staff writers Posted on 17 Jun 2015 |
The enumeration of nucleated red blood cell (NRBC) has been evaluated on a new automated hematology analyzer and to demonstrate the precision compared to manual counts (MC) at the various NRBC values.
The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.
Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.
The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.
In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.
The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Mahidol University
Sysmex Corporation
The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.
Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.
The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.
In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.
The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Mahidol University
Sysmex Corporation
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Hematology News
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Channels
Clinical Chemistry
view channel
Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more
Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
Diagnosing malignancy from pleural effusion remains challenging because tumor cells are rare and clusters are easily disrupted during processing. Conventional cytology can miss malignant tumor cells and... Read moreMolecular Diagnostics
view channel
AI Blood Test Enhances Monitoring of Liver Cirrhosis Progression
Monitoring chronic liver disease remains difficult because clinicians rely on tools that can be inconsistent and may miss early progression. Standard approaches often combine ultrasound imaging with blood-based... Read more
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more








